1. Norway Stocks

  2. •

    Process industries

  3. •

    Agricultural commodities/Milling
Aker BioMarine ASA

Aker BioMarine ASA

OOSL:AKBM
122.00
NOK
+7.60
(+6.64%)
5.26BMarket Cap
Oct 29Next Earn
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.14
0.27
0.02
0.01
34.41
2.23
3.56
3.7
2.99
3.16
2.24
2.27
2.49
- -
Basic EPS, GAAP
-0.69
-0.58
0.01
- -
-4.84
-0.01
-0.34
-0.07
-0.09
0.11
-0.1
2.08
-0.26
- -
Free Cash Flow per Basic Share
-1.31
-0.52
-0.01
-0.01
-15.63
-0.82
-1.66
-0.96
-0.9
-0.35
-0.02
-0.12
-0.06
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.26
- -
4.48
Book Value per Share
0.8
0.38
0.04
0.03
95.09
2.59
1.76
4.26
4.23
4.32
4.18
1.9
1.64
1.71
Tangible Book Value per Share
-0.04
-0.57
0.02
0.02
62.44
0.94
-0.41
2.2
2.27
2.46
2.41
0.5
0.31
0.31
Basic Weighted Avg Shares
90
90
528
955
2
69
69
78
88
88
88
88
88
83
Sales/Revenue/Turnover
12
24
9
9
84
154
246
289
262
277
196
199
218
- -
Operating Margin (%)
-244.71
-131.21
-25.48
-7.27
-3.2
6.65
0.67
1.66
-6.33
6.93
-5.3
-2.66
5.91
- -
Depreciation Expense
8
11
2
3
20
23
37
48
53
49
52
48
22
- -
Net Income, GAAP
-62
-52
5
-3
-12
-1
-24
-5
-8
10
-9
183
-23
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
894.04
- -
18.03
- -
- -
- -
- -
Profit Margin (%)
-507.06
-215.6
54.84
-34.24
-14.07
-0.66
-9.65
-1.89
-3.05
3.61
-4.58
91.76
-10.45
- -
Working Capital
28
-119
6
2
-52
27
83
152
162
194
177
142
121
121
LT Debt
181
17
12
15
36
179
372
211
294
334
344
140
159
158
Total Equity
72
34
37
32
232
179
155
373
370
379
367
167
144
150
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-9.34
- -
2.49
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-25.91
- -
3.66
- -
- -
- -
- -
Return on Common Equity (%)
-121.45
-99.42
14.12
-9.19
-8.94
-0.5
-14.25
-2.07
-2.15
2.67
-2.42
68.47
-14.67
- -

Capital Structure

USD

•

in mil. unless spec.
Sep'24
Dec'24
Jun'25
ST Debt
- -
7
25
LT Borrowings
- -
139
- -
LT Finance Leases
- -
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
88
88
Market Capitalization
409
520
522

Working Capital

USD

•

in mil. unless spec.
Sep'24
Dec'24
Jun'25
Total Current Assets
224
195
195
Cash, Cash Equivalents & STI
15
14
20
Accounts Receivable, Net
60
47
51
Inventories
110
89
102
Total Current Liabilities
61
53
74
Payables & Accruals
- -
- -
- -
ST Debt
- -
7
25
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
63.9%
-13.99%
-13.78%
Free Cash Flow
99.8%
53.85%
-55.05%
Net Income, GAAP
-44.53%
-521.99%
-112.49%
Sales/Revenue/Turnover
94.84%
-4.32%
9.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
78
49
49
52
199
2025
- -
- -
- -
- -
218
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
0.01
2.37
-0.18
2.08
2025
- -
- -
- -
- -
-0.26
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
4.26
- -
4.26
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Matts Eirik Johansen
Full Time Employees
258
Sector
Process industries
Industry
Agricultural commodities/Milling
Address
Oksenøyveien 10 Lysaker AK Norway 1327
IPO Date
Jul 6, 2020
Website
akerbiomarine.com
Similar Companies
Patanjali Foods Limited (NSE:PATANJALI)
Tilray Brands, Inc. (NASDAQ:TLRY)
Archer-Daniels-Midland Company (NYSE:ADM)
Corteva, Inc. (NYSE:CTVA)
Canopy Growth Corporation (NASDAQ:CGC)
Balrampur Chini Mills Ltd (NSE:BALRAMCHIN)
Business
Aker BioMarine AS (AKBM.OL) is a leading biotechnology company that harvests Antarctic krill and develops krill-derived ingredients for human health, nutrition, and emerging applications; it supplies high-quality omega-3 phospholipids, choline, astaxanthin, and proteins through a fully integrated supply chain from Antarctic harvesting to manufacturing facilities in Houston, Texas, and logistics in Montevideo, Uruguay. The company offers core products including Superba Krill Oil, a natural source of omega-3s, phospholipids, choline, and astaxanthin; Revervia, a premium algae oil with high DHA concentration; Lysoveta, a brain health supplement featuring LPC-bound EPA and DHA; PL+, a phospholipid delivery platform enhancing nutrient bioavailability; Understory, a sustainable protein with complete amino acid profile; AION, circular products from recycled marine plastic waste; Epion/Kori, a US consumer krill oil brand; CaPre, a therapeutic omega-3 candidate for cardiometabolic diseases; and KRBNX, biostimulants for agriculture. Founded in 2006 and headquartered in Lysaker, Norway, as a subsidiary of Aker ASA, Aker BioMarine operates globally with key markets in North America, Europe, Asia, and aquaculture regions, targeting nutraceutical manufacturers, consumer supplement brands, and research partners. In recent developments, Aker BioMarine sold its Feed Ingredients business, the world's largest krill meal producer for aquaculture, to a consortium led by American Industrial Partners and Aker Capital at a USD 590 million enterprise valuation in 2024, enabling a sharpened focus on human health and nutrition segments comprising Human Health Ingredients, Consumer Health Ingredients, and Emerging Businesses while securing a long-term krill raw material supply agreement. The company scaled up its circular partnership with AION in October 2025 to reduce packaging waste using recycled plastics; Lysoveta won innovation awards for brain health and healthy aging in 2025; it launched a digital platform unlocking 20 years of krill research and reported double-digit Q2 2025 revenue growth to USD 55.3 million with positive EBITDA momentum. Additional 2025 milestones include partnerships with European distributors for marine ingredients, clinical trial agreements for Lysoveta, appointments of key executives like CMO Jaroslava Juricova-Olsen and Houston GM Bob Nelson, and advocacy for Antarctic marine protection at CCAMLR and Clinton Global Initiative.